EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Pharmacological Treatments in Alcohol Use Disorder and Risk of Alcohol‐Related Hospitalizations: A Register Study

Patrick Bach iD, Johan Franck iD, Jonas Hällgren iD, Härje Widing iD, Mika Gissler iD, Jeanette Westman iD

Acta Psychiatrica Scandinavica · 2025

DOI: 10.1111/acps.13802 ↗

At a glance

Journal article in Acta Psychiatrica Scandinavica, 2025. Written by Patrick Bach and 5 co-authors. Institution: Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. Major MEDLINE topics: Registries, Hospitalization, Naltrexone, Alcoholism. Cited 5 times so far (Crossref); 31 references. The full text is freely available (open access, CC BY 4.0). Funded by: Forté Foundation, Karolinska Institutet, KID, The Swedish Research Council for Health, Working Life and Welfare (FORTE).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objectives

Despite the high prevalence of alcohol use disorder (AUD), only a minority of patients receive recommended pharmacological treatments, possibly owing to uncertainty about the real‐world effectiveness of these medications. Here, we analyzed nationwide, register‐based data to investigate the association between approved AUD medications (naltrexone, acamprosate, disulfiram, and nalmefene) and the risk of alcohol‐related hospitalizations among individuals with AUD.

Methods

People aged 18–64 with a registered first‐time diagnosis of AUD between 2009 and 2019 ( N = 93,727) were identified from the Swedish National Patient Register. Cox regression models were used to analyze the association between AUD medication exposure and the risk of alcohol‐related hospitalizations.

Results

Exposure to naltrexone (hazard ratio [HR] = 0.80; 95% confidence interval [CI] = 0.73 – 0.87) or disulfiram (HR = 0.83, 95% CI = 0.79 – 0.88) as monotherapy, or a combination of naltrexone/disulfiram (HR = 0.68, 95% CI = 0.49 – 0.96), or disulfiram/acamprosate (HR = 0.57 95% CI = 0.44 – 0.74) was significantly associated with a lower risk of alcohol‐related hospitalizations compared to periods without exposure to any of these medications. In contrast, no significant associations were observed for acamprosate, nalmefene, or the combination of acamprosate/naltrexone. Sensitivity analyses in individuals with severe AUD and stratified subgroup analyses by different socioeconomic groups confirmed the robustness of the results.

Conclusion

Results indicate a significant association between disulfiram and naltrexone monotherapy, as well as the combination of disulfiram with naltrexone or acamprosate, with a lower risk of alcohol‐related hospitalizations among individuals with AUD . Low prescription rates suggest that AUD medications are currently underutilized. Increasing the availability of these medications for individuals with AUD could help reduce alcohol‐related hospitalizations.

Subjects

MeSH terms (MEDLINE)

RegistriesHospitalizationNaltrexoneAlcoholismAlcohol DeterrentsHumansAdultMaleFemaleMiddle AgedDisulfiramAcamprosateSwedenYoung AdultAdolescentDrug Therapy, Combination

Author keywords

acamprosatealcohol use disorderdisulfiramhospitalizationmedicationnaltrexone

Substances

NaltrexoneDisulfiramAlcohol DeterrentsAcamprosatenalmefene

Authors and institutions

  • Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, University of Heidelberg, Medical Faculty Mannheim, Mannheim, Germany.
  • Department of Data and Analytics, Finnish Institute for Health and Welfare, Helsinki, Finland.
  • Academic Primary Care Centre. Region Stockholm, Stockholm, Sweden.
  • Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
  • Department of Child Psychiatry, Turku University Hospital, Turku University, Turku, Finland.

ORCID profiles: Patrick Bach, Johan Franck, Jonas Hällgren, Härje Widing, Mika Gissler, Jeanette Westman

Funding

  • Forté Foundation
  • Karolinska Institutet, KID
  • The Swedish Research Council for Health, Working Life and Welfare (FORTE)
  • Region Stockholm
  • Karolinska Institutet

Cite

APA

Bach, P., Franck, J., Hällgren, J., Widing, H., Gissler, M., & Westman, J. (2025). Pharmacological Treatments in Alcohol Use Disorder and Risk of Alcohol‐Related Hospitalizations: A Register Study. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/acps.13802

Vancouver

Bach P, Franck J, Hällgren J, Widing H, Gissler M, Westman J. Pharmacological Treatments in Alcohol Use Disorder and Risk of Alcohol‐Related Hospitalizations: A Register Study. Acta Psychiatrica Scandinavica. 2025. doi:10.1111/acps.13802

BibTeX
@article{Bach2025,
  author = {Bach, Patrick and Franck, Johan and Hällgren, Jonas and Widing, Härje and Gissler, Mika and Westman, Jeanette},
  title = {Pharmacological Treatments in Alcohol Use Disorder and Risk of Alcohol‐Related Hospitalizations: A Register Study},
  journal = {Acta Psychiatrica Scandinavica},
  year = {2025},
  doi = {10.1111/acps.13802}
}
Start for free →